Xenon (XENE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xenon Pharmaceuticals has unveiled promising long-term data from its X-TOLE study, showing that its drug azetukalner significantly reduces seizure frequency in patients with focal onset seizures. Impressively, one-third of those treated for over three years achieved complete seizure freedom, highlighting the drug’s potential to improve epilepsy treatment.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.